176
|
Hou X, Wang YJ, Yin QX, Miao JL, Jiang H. Prevention of contrast-induced nephropathy comparison of two hydration regimens in elderly patients undergoing percutaneous coronary intervention. BRITISH HEART JOURNAL 2011. [DOI: 10.1136/heartjnl-2011-300867.675] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
177
|
Yin Q, Zhao Y, Hou X. Long-term trends in 30-day mortality of hospitalised patients with heart failure: between 1993 and 2007. BRITISH HEART JOURNAL 2011. [DOI: 10.1136/heartjnl-2011-300867.626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
178
|
Delaney A, Talbott H, Yu Y, Ramey J, Hou X, Davis J. Rapid induction of interleukin 8 (IL8) expression during prostaglandin F2alpha induced regression of the corpus luteum: role in neutrophil degranulation and chemotaxis. Fertil Steril 2011. [DOI: 10.1016/j.fertnstert.2011.07.544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
179
|
Rashid MH, Lee M, Koh R, Chew M, Hou X, Foo K, Choo S, Koo W, Ong S, Quek R. 9434 POSTER Localized Colorectal (CLR) Gastrointestinal Stromal Tumour (GIST) -Clinical Characteristics, Patterns of Relapse and Clinical Outcomes of This Uncommon GIST Primary Site. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72578-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
180
|
Keene KL, Quinlan AR, Hou X, Hall IM, Mychaleckyj JC, Onengut-Gumuscu S, Concannon P. Evidence for two independent associations with type 1 diabetes at the 12q13 locus. Genes Immun 2011; 13:66-70. [PMID: 21850031 PMCID: PMC3285513 DOI: 10.1038/gene.2011.56] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Genome-wide association studies have identified associations between type 1 diabetes and single nucleotide polymorphisms (SNPs) at chromosome 12q13, surrounding the gene ERBB3. Our objective was to fine map this region to further localize causative variants. Re-sequencing identified more than 100 putative SNPs in an 80 kb region at 12q13. By genotyping 42 SNPs, spanning approximately 214 kb, in 382 affected sibling pair type 1 diabetes families, we were able to genotype or tag 67 common SNPs (MAF ≥ 0.05) identified from HapMap CEU data and CEU data from the 1000 Genomes Project, plus additional rare coding variants identified from our re-sequencing efforts. Fifteen SNPs provided nominal evidence for association (P≤ 0.05) with type 1 diabetes. The most significant associations were observed with rs2271189 (P = 4.22×10−5), located in exon 27 of the ERBB3 gene, and an intergenic SNP rs11171747 (P= 1.70×10−4). Follow-up genotyping of these SNPs in 2 740 multiplex type 1 diabetes families validated these findings. After analyzing variants spanning more than 200 kb, we have replicated associations from previous GWAS and provide evidence for novel associations with type 1 diabetes. The associations across this region could be entirely accounted for by two common SNPs, rs2271189 and rs11171747.
Collapse
|
181
|
Celler A, Hou X, Bénard F, Ruth T. Theoretical modeling of yields for proton-induced reactions on natural and enriched molybdenum targets. Phys Med Biol 2011; 56:5469-84. [DOI: 10.1088/0031-9155/56/17/002] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
182
|
Hou X, Grimes J, Benard F, Ruth TJ, Celler A. MO-F-110-08: Yields and Dosimetry Estimates for Radioisotopes Produced in Proton-Induced Reactions on Enriched Molybdenum Targets. Med Phys 2011. [DOI: 10.1118/1.3613030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
183
|
Haluska P, Dhar A, Hou X, Huang F, Nuyten DSA, Park J, Brodie AH, Ingle JN, Carboni JM, Gottardis MM, Wolff AC, Finckenstein FG. Phase II trial of the dual IGF-1R/IR inhibitor BMS-754807 with or without letrozole in aromatase inhibitor-resistant breast cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps111] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
184
|
Tai WM, Tang PL, Koo YX, Hou X, Tay KW, Quek R, Tao M, Lim ST. Do We Have the Right Prognostic Index for Diffuse Large B Cell Lymphoma (DLBCL) in the Era of Rituximab? PROCEEDINGS OF SINGAPORE HEALTHCARE 2011. [DOI: 10.1177/201010581102000108] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Introduction: Whilst the addition of rituximab, a humanized monoclonal antibody to standard CHOP chemotherapy (R-CHOP) has improved the outcomes of DLBCL, the validity of the previously identified prognostic index based on clinical parameters is questioned. It is conceivable that prognostic model may alter with introduction of new therapeutics with differing efficacy and mechanisms of action. Methods: We conducted a retrospective analysis comparing the relevance of International Prognostic Index (IPI), Age-adjusted IPI and Revised International Prognostic Index (R-IPI) in 320 consecutive patients with DLBCL from 2003–2008 treated with R-CHOP chemotherapy with curative intent. We evaluated the prognostic factors determinant of survival in our group of patients. Results: Patients were followed up for a median of 2.70 years. IPI was only able to stratify patients into 3 main risk groups instead of 4. In addition, among patients <60, aa-IPI no longer seem a robust prognostic model. We showed that R-IPI was able to separate patients into 3 different prognostic groups and perhaps most relevant in the era of chemo-immunotherapy. Significant prognostic factors identified in multivariate analysis were performance status (P=0.004) and bone marrow involvement (P=0.026). Conclusion: The most robust prognostic index for patients with DLBCL in the era of rituximab remains uncertain. Incorporation of molecular markers into clinical parameters should be evaluated, a study we are embarking on.
Collapse
|
185
|
Wong M, Yip C, Hou X, Tan P, Huang H, Chowbay B, Lau W, Tan T, Tan M, Wong F. Validation of the AJCC staging system (7th edition) in Asian patients with localized prostate cancer undergoing radical radiotherapy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
112 Background: The epidemiology of prostate cancer (PCa) varies widely internationally. Although prostate cancer is usually regarded as uncommon in Asia, dramatic rises in recent years have resulted in it being ranking third by incidence in Singapore. Conventional prognostic parameters derived from Western populations have been integrated into systems such as the new AJCC seventh edition staging system, the validity of which is unclear in Asia. We thus sought to validate its performance, alongside other prognostic factors in a large Asian series of radiotherapy patients. Methods: A retrospective review of 404 consecutive Singaporean patients receiving radical radiotherapy between 1997 and 2005 at the National Cancer Centre was performed. The primary outcome was biochemical relapse free survival (BRFS), defined by the Phoenix criteria. Prognostic risk groups were defined using AJCC seventh edition. Univariate analysis (UVA) and multivariate analysis (MVA) was performed for other putative risk factors: age, race, Gleason score, prognostic risk grouping, tumour classification, radiation delivery technique, radiotherapy dose, hormonal therapy (HT) and initial PSA. Results: Median age was 69; median BRFS was 55 months with 71 biochemical relapses. 4 risk factors showed univariate association with BRFS: AJCC risk groups (p=0.038), T-stage (p=0.018), RT dose (p=0.025) and initial PSA value (p=0.013) with AJCC risk groups and initial PSA value remaining significant after MVA ( Table ). Harrell's c-index for AJCC risk grouping was 0.56, with no significant difference seen in outcomes between AJCC risk group II and III. Conclusions: Our results validate the new AJCC seventh edition prostate cancer prognostic risk grouping in an Asian radiotherapy population for the first time; the actual association however is relatively weak possibly due to differences in biology, screening or epidemiology. [Table: see text] No significant financial relationships to disclose.
Collapse
|
186
|
Farzan T, Harrington S, Krempski J, Weroha S, Hou X, Kalli K, Haluska P. Combined erbB/VEGFR blockade has improved anticancer activity over single-pathway inhibition in ovarian cancer in vivo. Gynecol Oncol 2011. [DOI: 10.1016/j.ygyno.2010.12.110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
187
|
Zhang F, Chen M, Yang B, Chen H, Ju W, Hou X, Cao K, Tao H, Zhang J, Li L, Jia YH, Chu JM, Ding LG, Zhao YJ, Wei W, Wang J, Zhang S, Suenaga H, Saito S, Zheng L, Yao Y, Zhang S, Zhang K, Chen W, Li J, Wang F, Chen X. VT Ablation II. Europace 2011. [DOI: 10.1093/europace/euq468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
188
|
Yaduvanshi A, Kumar M, Kataria V, Arora V, Nair M, Ardashev AV, Rybachenko MS, Zhelyakov EG, Konev AV, Xv D, Yang B, Chen M, Zhang F, Ju W, Chen H, Zhai L, Wang J, Yu J, Shan Q, Zou J, Chen C, Hou X, Cao K, Termosesov S, Garipov R, Ilich I, Volkova Y, Zhang F, Chen M, Yang B, Chen H, Ju W, Xu D, Zou J, Shan Q, Cao K, Liu J, Fang PH, Hou Y, Jia YH, Chu JM, Yao Y, Ma J, Pu JL, Zhang S. Catheter Ablation. Europace 2011. [DOI: 10.1093/europace/euq469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
189
|
Yang B, Chen M, Zhang F, Ju W, Chen H, Zhai L, Yang H, Wang J, Yu J, Shan Q, Zou J, Chen C, Hou X, Cao K, Chi SY, Ho D, Wong SP, Prasertwitayakij N, Vodnala D, Pridjian AK, Thakur RK, Tan VH, Lee L, Wah LB, Tan M, Khurana R, Liew R, Chow J, Madras A, Arena F, Barin E, Figtree G. Case Reports I. Europace 2011. [DOI: 10.1093/europace/euq486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
190
|
Yang B, Chen M, Zhang F, Ju W, Chen H, Zhao W, Zhai L, Wang J, Yu J, Shan Q, Zou J, Chen C, Dongjie X, Hou X, Cao K, Dong YX, Yang YZ, Oh JK, Mitsuru M, Powell BD, Larson MD, Buescher TL, Hodge DO, Packer DL, Cha YM, Liu J, Fang P, Hou Y, Li X, Hou C, Ma J, Pu J, Zhang S, Ju W, Yang B, Chen H, Zhang F, Zhai L, Cao K, Chen M, Yu S, Zhao Q, Qin M, Cui H, Huang H, Huang C. AF Ablation III. Europace 2011. [DOI: 10.1093/europace/euq472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
191
|
Tai WM, Chung J, Tang PL, Koo YX, Hou X, Tay KW, Quek R, Tao M, Lim ST. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Ann Hematol 2011. [PMID: 21229246 DOI: 10.1007/s00277‐010‐1150‐7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/29/2022]
Abstract
Central nervous system (CNS)-directed prophylactic intrathecal (IT) therapy is indicated in patients with Burkitt and acute lymphoblastic lymphoma. Its role in diffuse large B cell lymphoma (DLBCL), a heterogeneous subtype, is less well defined. While addition of rituximab to standard cyclophosphamide-hydroxydaunorubicin-oncovin-prednisone (CHOP) chemotherapy (R-CHOP) has improved the outcomes of DLBCL patients, its role in reducing CNS relapse is unclear. We aim to (1) evaluate the clinical risk factors predictive of CNS relapse, (2) the role of rituximab in influencing CNS relapse, and (3) role of intrathecal prophylaxis. Four hundred ninety-nine patients with DLBCL from 2000 to 2008 were included (CHOP 179 vs. R-CHOP 320). IT prophylaxis was administered to 82 patients based on our institution's guidelines. Baseline characteristics between CHOP- and R-CHOP-treated patients were similar. Although R-CHOP significantly increased the complete remission rate from 71% to 81% (P < 0.01), CNS relapse rates remained unchanged (R-CHOP 6% vs. CHOP 5.1%). On multivariate analysis, poor performance status (Eastern Cooperative Oncology Group >1; hazard ratio (HR) = 2.01, 95% confidence interval (CI) 1.29-3.14), failure to attain remission (non-complete response (CR) vs. CR: HR = 2.39, 95% CI = 1.03 to 5.51), testicular (HR = 6.67, 95% CI = 1.62 to 27.53), kidney (HR = 20.14, 95% CI = 5.23 to 77.46), and breast involvement (HR = 6.14, 95% CI = 1.61 to 23.37) were each independently predictive of CNS relapse. Use of IT prophylaxis did not appear to decrease CNS relapse. Median survival after CNS relapse was 3.2 months. CNS relapse, a fatal event, remains a challenge in R-CHOP-treated patients. IT prophylaxis may not be sufficient to reduce CNS relapse, and strategies including systemic agents with high CNS penetration should be evaluated in high-risk patients identified in this study.
Collapse
|
192
|
Tai WM, Chung J, Tang PL, Koo YX, Hou X, Tay KW, Quek R, Tao M, Lim ST. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Ann Hematol 2011; 90:809-18. [PMID: 21229246 DOI: 10.1007/s00277-010-1150-7] [Citation(s) in RCA: 97] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2010] [Accepted: 12/22/2010] [Indexed: 11/24/2022]
Abstract
Central nervous system (CNS)-directed prophylactic intrathecal (IT) therapy is indicated in patients with Burkitt and acute lymphoblastic lymphoma. Its role in diffuse large B cell lymphoma (DLBCL), a heterogeneous subtype, is less well defined. While addition of rituximab to standard cyclophosphamide-hydroxydaunorubicin-oncovin-prednisone (CHOP) chemotherapy (R-CHOP) has improved the outcomes of DLBCL patients, its role in reducing CNS relapse is unclear. We aim to (1) evaluate the clinical risk factors predictive of CNS relapse, (2) the role of rituximab in influencing CNS relapse, and (3) role of intrathecal prophylaxis. Four hundred ninety-nine patients with DLBCL from 2000 to 2008 were included (CHOP 179 vs. R-CHOP 320). IT prophylaxis was administered to 82 patients based on our institution's guidelines. Baseline characteristics between CHOP- and R-CHOP-treated patients were similar. Although R-CHOP significantly increased the complete remission rate from 71% to 81% (P < 0.01), CNS relapse rates remained unchanged (R-CHOP 6% vs. CHOP 5.1%). On multivariate analysis, poor performance status (Eastern Cooperative Oncology Group >1; hazard ratio (HR) = 2.01, 95% confidence interval (CI) 1.29-3.14), failure to attain remission (non-complete response (CR) vs. CR: HR = 2.39, 95% CI = 1.03 to 5.51), testicular (HR = 6.67, 95% CI = 1.62 to 27.53), kidney (HR = 20.14, 95% CI = 5.23 to 77.46), and breast involvement (HR = 6.14, 95% CI = 1.61 to 23.37) were each independently predictive of CNS relapse. Use of IT prophylaxis did not appear to decrease CNS relapse. Median survival after CNS relapse was 3.2 months. CNS relapse, a fatal event, remains a challenge in R-CHOP-treated patients. IT prophylaxis may not be sufficient to reduce CNS relapse, and strategies including systemic agents with high CNS penetration should be evaluated in high-risk patients identified in this study.
Collapse
|
193
|
Gudelis A, Druteikiene R, Luksiene B, Gvozdaite R, Nielsen SP, Hou X, Mazeika J, Petrosius R. Assessing deposition levels of 55Fe, 60Co and 63Ni in the Ignalina NPP environment. JOURNAL OF ENVIRONMENTAL RADIOACTIVITY 2010; 101:464-467. [PMID: 18818005 DOI: 10.1016/j.jenvrad.2008.08.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/30/2007] [Revised: 06/12/2008] [Accepted: 08/06/2008] [Indexed: 05/26/2023]
Abstract
Two RBMK-1500 reactor units operated in Lithuania in the 1987-2004 period (one of them was stopped for decommissioning in 2004). This study presents a preliminary investigation of surface deposition density levels of (55)Fe and (63)Ni in moss samples collected in the close vicinity of the Ignalina NPP. Non-destructive analysis by the HPGe gamma-spectrometry was followed by radiochemical separation. Radiochemical analysis was based on anion-exchange and extraction chromatography. (55)Fe and (63)Ni activities were measured by liquid scintillation counting (LSC). The results indicate that the deposition values of (55)Fe are generally higher than those of (60)Co and (63)Ni.
Collapse
|
194
|
Pang R, Zhang Y, Pan X, Gu R, Hou X, Xiang P, Liu Z, Zhu X, Hu J, Zhao J, Zhang C. Embryonic-like stem cell derived from adult bone marrow: immature morphology, cell surface markers, ultramicrostructure and differentiation into multinucleated fibers in vitro. Cell Mol Biol (Noisy-le-grand) 2010; 56 Suppl:OL1276-OL1285. [PMID: 20385079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2009] [Accepted: 02/15/2010] [Indexed: 05/29/2023]
Abstract
Embryonic-like stem cell (ELSC), expressing part of surface markers of human embryonic stem cells, may be a better candidate for cell therapy of degenerative muscular disease than mesenchymal stem cell (MSC). We isolated ELSC and MSC from bone marrow, respectively, and compared their differences in the characteristics and the capacity of myogenic differentiation. Results showed that ELSC could be isolated successfully from 3 adult bone marrow samples by using serum-free medium with 10ng/ml basic fibroblast growth factor (bFGF). At the same cell density, MSC could also be isolated from the same samples by using DMEM/F12 medium containing 10% new cattle serum. However, ELSC appeared as small, morphologically slenderer, upregulated expression of SSEA-4 and ultramicroscopically more immature than MSC derived from the same samples. Immunofluorescent staining and RT-PCR analysis showed ELSC weakly expressed Oct-4, Nanog-3 and Sox-2. Moreover, ELSC and MSC could be induced into long, multinucleated fibers expressing myogenin and myosin heavy chain (MHC) in myogenic differentiation medium, but by day 10, proportion of multinucleated fibers positive for MHC was respectively 25.0%+/-6.9% and 13.8%+/-7.6% in ELSC and MSC culture. These data suggest that bone marrow derived ELSC represent an ideal candidate for cell therapy of degenerative muscular disease.
Collapse
|
195
|
Li C, Liu S, Guan Y, Qian W, du F, Hou X. Long pulse gastric electrical stimulation induces regeneration of myenteric plexus synaptic vesicles in diabetic rats. Neurogastroenterol Motil 2010; 22:453-61, e108. [PMID: 19886913 DOI: 10.1111/j.1365-2982.2009.01420.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
BACKGROUND Gastric electrical stimulation (GES) may improve delayed gastric emptying in diabetic gastroparesis, but whether enteric nervous system (ENS) is directly involved in its mechanism of improvement in gastric motility is unclear. The aims were to investigate the correlation between the changes in ENS and effects of long pulse GES on them in diabetic rats induced by streptozotocin (STZ). METHODS Electron microscopy, immunohistochemistry, RT-PCR and western blot were used to evaluate changes of myenteric plexus neurons and synaptic vesicles in different stages of the diabetic rats. The effects of GES were detected by same methods after pacing wires were implanted and then diabetes was induced and followed by long pulse GES. KEY RESULTS Since 6 weeks after STZ injection, the nerve fibres were incompact and synaptic vesicles in myenteric neurons reduced. Furthermore, the myenteric neurons showed severe damage such as partial depletion of the axon, swelling of mitochondria and seriously decreased synaptic vesicles in 12 weeks after STZ injection. The synaptophysin and PGP9.5-positive area and expressions of synaptophysin mRNA and protein decreased with the duration of diabetes. Long pulse GES could induce increase of myenteric neuronal synaptic vesicles, synaptophysin and PGP9.5-positive area and in myenteric plexus. The synaptophysin mRNA and protein expression rose after GES, whatever GES beginning early or late, short-term or long-term. CONCLUSIONS & INFERENCES The longer duration of diabetes, the more significant damages to myenteric neurons and synaptic vesicles of diabetic rats; long pulse GES could induce regeneration of myenteric plexus synaptic vesicles, thereby reform gastric motility.
Collapse
|
196
|
LeMaire S, Lu X, Hou X, Russell L, Milewicz D, Belmont J, Adams G, Shen Y, Coselli J. Abstracts of the Fifth Annual Academic Surgical Congress of the Association for Academic Surgery and Society of University Surgeons. San Antonio, Texas, USA. February 3-5, 2010. J Surg Res 2010; 158:171-424. [PMID: 20105706 DOI: 10.1016/j.jss.2009.11.014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
197
|
Hou X, Li Y, Wu G, Wang L, Hong M, Wu Y. Determination of Para Red, Sudan Dyes, Canthaxanthin, and Astaxanthin in Animal Feeds Using UPLC. J Chromatogr Sci 2010; 48:22-5. [DOI: 10.1093/chromsci/48.1.22] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
198
|
Haluska P, Hou X, Huang F, Harrington S, Greer A, Macedo L, Brodie A, Evans D, Carboni J, Gottardis M. Complete IGF Signaling Blockade by the Dual-Kinase Inhibitor, BMS-754807, Is Sufficient To Overcome Tamoxifen and Letrozole Resistance In Vitro and In Vivo. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-402] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Resistance to hormonal therapy is a clinically unmet need in breast cancer. IGF signaling has been identified as a major mechanism of resistance to hormonal therapy in breast cancer. As components of the IGF signaling pathway are expressed in most breast cancers, the development of IGF-1R monoclonal antibody (mAb) and tyrosine kinase inhibitors (TKI) are active areas of clinical investigations. A key distinction between the mAb and TKIs are their differences in their ability to inhibit the Insulin Receptor (InsR). While targeting the InsR with TKIs may have a theoretical liability of hyperglycemia, targeting only the IGF-1R may have the theoretical liability of incompletely blocking IGF signaling. As InsR isoform A expression, which can transduce IGF-II-mediated proliferation, is higher in breast cancers compared to normal breast tissue, we investigated whether IGF-1R or IGF-1R/InsR inhibition was sufficient for overcoming resistance to hormonal therapy. To determine the optimal combination strategies for clinical investigations, we tested the hypothesis that IGF signaling inhibition could overcome primary (or de novo/intrinsic) and secondary (or acquired/selected) resistance to hormonal therapy. For these studies, we used either hormone therapy-naïve or hormone therapy-resistant variants of the breast cancer model, MCF-7/AC-1, which has been engineered to stably express full-length human aromatase. We employed and compared a novel, potent dual kinase inhibitor of the IGF-1R and InsR, BMS-754807, which is currently in early clinical investigations, with the IGF-1R antibody mAb391. BMS-754807 has been shown to induce apoptosis more potently than mAb391 in Rh41 human rhabdomyosarcoma cells. In vitro, BMS-754807 demonstrated profound synergy in combination with tamoxifen and letrozole (median effect combination index <0.1). In vivo, BMS-754807 enhanced the anti-tumor activity of tamoxifen and letrozole in hormone-naïve tumors and induced regression of tumors resistant to tamoxifen or letrozole when combined with letrozole. This activity was not observed with mAb therapy, which resulted in greater up-regulation of InsR-A and erbB receptor expression and activation. This suggested a greater susceptibility to resistance pathways with mAb therapy. Dual IGF-1R/InsR blockade alone or in combination was tolerated by the animals and has no significant change in glucose homeostasis. Gene expression profiling experiments to compare the difference between the effects of tamoxifen in combination with BMS-754807 and with mAb revealed alternative pathway signaling is one of the potential mechanisms of resistance.In summary, combined hormonal therapy with BMS-754807 overcomes primary and secondary resistance to tamoxifen and letrozole and was well tolerated. IGF-1R blockade with a mAb alone is insufficient to overcome resistance and induces InsR over-expression. Thus, IGF signaling through either InsR or IGF-1R may be a major mechanism of resistance to hormonal therapy. These data suggest that blockade of IGF-1 and IGF-II from activation of IGF-1R and InsR, with agents such as BMS-754807 have promise in extending the benefits of hormonal therapy in breast cancer.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 402.
Collapse
|
199
|
Tian X, Ma L, Huang Y, Lu J, Hou X, Hong K, Wang G, Zhao L. VID-07.02: Pre-Peritoneal Laparoscopic Partial Cystectomy of Bladder Pheochromocytoma. Urology 2009. [DOI: 10.1016/j.urology.2009.07.669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
200
|
Dong X, Zhu L, Wang J, Wang J, Xie H, Hou X, Jia W. Effects of atrazine on cytochrome P450 enzymes of zebrafish (Danio rerio). CHEMOSPHERE 2009; 77:404-412. [PMID: 19647285 DOI: 10.1016/j.chemosphere.2009.06.052] [Citation(s) in RCA: 85] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/09/2009] [Revised: 05/27/2009] [Accepted: 06/22/2009] [Indexed: 05/28/2023]
Abstract
In this study, the effects of atrazine (2-chloro-4-ethylamino-6-isopropylamino-1,3,5-triazine) in males and females of adult zebrafish (Danio rerio) were studied. The liver microsomal cytochrome P450 content, NADPH-P450 reductase, aminopyrine N-demethylase (APND), and erythromycin N-demethylase (ERND) activity were measured. Zebrafish were exposed to control and 3 treatments (0.01, 0.1, and 1 mg L(-1)) of atrazine for 5, 10, 15, 20, and 25 days. The results indicated that, within the range of test atrazine concentrations, either P450 content or P450 isozyme activities could be induced by atrazine. Compared to controls, P450 content was significantly increased at all atrazine concentrations at days 10, 15, and 20; thereafter, at day 25, all concentrations decreased to approximately the control levels, both in males and females. In addition, the strongest induction of P450 content was observed on day 15 in males and day 10 in females at treatment concentrations of 1 mg L(-1). NADPH-P450 reductase activities showed mild increase in males; however, the females exhibited significant induction on days 15, 20, and 25; especially, at concentrations of 0.01 mg L(-1), the induction level was consistently increased during the experiment. The inducements of APND and ERND in males were mainly observed on the days 5, 10, and 15, which showed less distinct induction, while significant induction was observed in cases of treatments during all days in females. In conclusion, atrazine induces P450 enzymes in zebrafish, and the effects may function as significant toxicity mechanisms in zebrafish. Additionally, it also confirms the importance of using a combined multi-time and multi-index diagnostic method to enhance the sensitivity and effectiveness of the indices adopted.
Collapse
|